Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:16 am
Author: Getaka|Social: XLinkedIn

Lyka Labs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹32.25Overvalued by 37.01%vs CMP ₹51.20

P/E (15.0) × ROE (9.3%) × BV (₹28.30) × DY (2.00%)

Defaults: P/E=15

₹29.05Overvalued by 43.26%vs CMP ₹51.20
MoS: -76.2% (Negative)Confidence: 59/100 (Moderate)Models: 1 Under, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹18.8222%Over (-63.2%)
Graham NumberEarnings₹37.7717%Over (-26.2%)
DCFCash Flow₹13.1217%Over (-74.4%)
Net Asset ValueAssets₹28.269%Over (-44.8%)
EV/EBITDAEnterprise₹60.9911%Under (+19.1%)
Earnings YieldEarnings₹22.409%Over (-56.3%)
ROCE CapitalReturns₹28.449%Over (-44.5%)
Revenue MultipleRevenue₹38.617%Over (-24.6%)
Consensus (8 models)₹29.05100%Overvalued
Key Drivers: EPS CAGR -41.6% drags value — could be higher if earnings stabilize. | Wide model spread (₹13–₹61) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -41.6% · Defaults: P/E=15

*Investments are subject to market risks

Analyst Summary

Lyka Labs Ltd operates in the Pharmaceuticals segment, current market price is ₹51.20, market cap is 183 Cr.. At a glance, ROE is 9.31 %, ROCE is 9.91 %, book value is 28.3, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹29.05, around 43.3% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹138 Cr versus the prior period change of 24.3%, while latest net profit is about ₹8 Cr with a prior-period change of 366.7%. This analysis page also carries profit and loss, shareholding pattern, ratio panels data, which improves the depth of the template beyond a thin price-only snapshot. The 52-week range shown on this page is 129/44.1, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisLyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738. Currently Company is involved in t…

This summary is generated from the stock page data available for Lyka Labs Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

42
Lyka Labs Ltd scores 42/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health50/100 · Moderate
ROCE 9.9% AverageROE 9.3% AverageD/E -6.24 Low debtInterest Coverage 0.0x RiskyProfitable 2/5 years Inconsistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 58.2% Stable
Earnings Quality40/100 · Moderate
OPM contracting (35% → 14%) Declining
Quarterly Momentum30/100 · Weak
Revenue (4Q): 1% YoY FlatProfit (4Q): -109% YoY DecliningOPM: 5.4% (down 10.0% YoY) Margin pressure
Industry Rank40/100 · Moderate
ROCE 9.9% vs industry 16.4% Average3Y sales CAGR: -11% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:16 am

Market Cap 183 Cr.
Current Price 51.2
Intrinsic Value₹29.05
High / Low 129/44.1
Stock P/E
Book Value 28.3
Dividend Yield0.00 %
ROCE9.91 %
ROE9.31 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lyka Labs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lyka Labs Ltd 183 Cr. 51.2 129/44.1 28.30.00 %9.91 %9.31 % 10.0
Nectar Lifescience Ltd 190 Cr. 9.76 28.3/9.20 32.00.00 %5.36 %11.2 % 1.00
Auro Laboratories Ltd 169 Cr. 272 317/15957.4 69.90.00 %3.85 %4.33 % 10.0
Ambalal Sarabhai Enterprises Ltd 203 Cr. 26.5 42.0/23.111.4 19.20.00 %9.12 %6.25 % 10.0
Gennex Laboratories Ltd 208 Cr. 8.55 17.2/7.0511.9 8.790.00 %13.0 %10.2 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Lyka Labs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 17.8222.2422.8827.9932.5627.7730.1141.1633.8033.4333.0336.6630.73
Expenses 15.6118.9420.2423.8225.6925.7526.4036.2128.6129.3529.3539.2029.08
Operating Profit 2.213.302.644.176.872.023.714.955.194.083.68-2.541.65
OPM % 12.40%14.84%11.54%14.90%21.10%7.27%12.32%12.03%15.36%12.20%11.14%-6.93%5.37%
Other Income -5.950.020.38-0.180.540.320.560.030.830.820.631.091.16
Interest 3.082.851.351.191.281.070.650.540.610.470.850.790.82
Depreciation 3.473.473.473.592.842.901.761.761.831.422.112.152.15
Profit before tax -10.29-3.00-1.80-0.793.29-1.631.862.683.583.011.35-4.39-0.16
Tax % 2.24%0.00%7.22%-22.78%38.60%28.22%30.65%28.36%24.30%32.89%26.67%-26.65%-6.25%
Net Profit -10.42-3.01-1.85-0.491.78-2.091.291.912.702.030.99-3.22-0.15
EPS in Rs -3.63-0.98-0.56-0.150.54-0.630.400.590.760.500.26-0.940.00

Last Updated: March 4, 2026, 1:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 9:46 pm

MetricJun 2014n n 15mJun 2015Mar 2016n n 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1191661301106071618619493111138134
Expenses 1111391108763736567937695121127
Operating Profit 8282023-4-2-4201011716187
OPM % 7%17%16%21%-6%-3%-6%23%52%18%14%13%5%
Other Income 2548-241-300-4-4124
Interest 2724151910720262012523
Depreciation 9119101178817141378
Profit before tax -3-34-8-20-15-62-1459-13-111-0
Tax % 45%31%-5%-19%-5%-59%1%-29%35%-0%182%29%
Net Profit -5-54-7-19-6-63-1038-13-38-0
EPS in Rs -3.05-2.291.67-2.51-6.14-1.97-21.10-4.0313.59-4.30-0.752.24-0.18
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-171.43%68.42%-950.00%84.13%480.00%-134.21%76.92%366.67%
Change in YoY Net Profit Growth (%)0.00%239.85%-1018.42%1034.13%395.87%-614.21%211.13%289.74%

Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:2%
5 Years:18%
3 Years:-11%
TTM:19%
Compounded Profit Growth
10 Years:9%
5 Years:18%
3 Years:-43%
TTM:681%
Stock Price CAGR
10 Years:4%
5 Years:39%
3 Years:-13%
1 Year:-40%
Return on Equity
10 Years:%
5 Years:%
3 Years:0%
Last Year:9%

Last Updated: September 5, 2025, 9:55 am

Balance Sheet

Last Updated: December 4, 2025, 1:35 am

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 22222222282829292931333636
Reserves 302022162115-43-54-1515356865
Borrowings 1641371211261139614116313075593932
Other Liabilities 1131007788677673524231303335
Total Liabilities 329279242252229216200190186152157176168
Fixed Assets 162122104133116108105989468588587
CWIP 222730242831282618162311
Investments 0000000000000
Other Assets 14513010794857768667467769080
Total Assets 329279242252229216200190186152157176168

Reserves and Borrowings Chart

Cash Flow

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 8927123111275979922
Cash from Investing Activity + -573717-13-3-4-0-0-67-9-12
Cash from Financing Activity + -26-60-30-19-10-233-12-63-2225
Net Cash Flow 64-1-0-3-19-310-5-6-5
Free Cash Flow 25552818723487215-7-10
CFO/OP 1,059%97%60%143%-318%-1,462%-131%49%79%52%21%28%

Free Cash Flow

MonthJun 2014n n 15mJun 2015Mar 2016n n 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow8.00-109.0020.00-103.00-117.00-98.00-145.00-143.00-29.00-58.00-43.00-21.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 20912412197125754837357989114
Inventory Days 9177569013965694156687882
Days Payable 36322021826630121619214196919898
Cash Conversion Cycle -64-18-41-79-37-75-76-63-5556897
Working Capital Days -309-220-242-357-735-265-242-118-121-02351
ROCE %2%10%7%9%-8%-5%-6%10%61%5%4%10%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 51.00%54.58%54.81%54.81%54.81%58.11%58.11%58.11%58.16%58.16%58.16%58.16%
FIIs 0.18%0.17%0.18%0.17%0.17%0.15%0.15%0.15%0.24%0.16%0.17%0.17%
DIIs 3.74%0.41%0.41%0.62%0.81%0.75%0.66%0.66%0.66%0.66%0.66%0.66%
Public 45.08%44.84%44.61%44.41%44.21%40.99%41.08%41.07%40.93%41.02%40.99%40.99%
No. of Shareholders 26,82027,20226,65226,42225,71725,71628,94329,09928,47228,18927,74327,155

Shareholding Pattern Chart

No. of Shareholders

Lyka Labs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 2.22-0.79-4.6313.57-4.07
Diluted EPS (Rs.) 2.22-0.79-4.6313.57-4.07
Cash EPS (Rs.) 4.123.080.3219.45-0.61
Book Value[Excl.RevalReserv]/Share (Rs.) 29.0120.6014.814.70-8.75
Book Value[Incl.RevalReserv]/Share (Rs.) 29.0120.6014.814.70-8.75
Revenue From Operations / Share (Rs.) 38.8133.6030.3367.6530.06
PBDIT / Share (Rs.) 5.655.196.5935.997.41
PBIT / Share (Rs.) 3.751.321.9929.944.50
PBT / Share (Rs.) 3.12-0.28-4.2920.65-4.93
Net Profit / Share (Rs.) 2.22-0.79-4.2913.40-3.52
NP After MI And SOA / Share (Rs.) 2.24-0.75-4.3013.59-4.03
PBDIT Margin (%) 14.5615.4421.7453.1924.63
PBIT Margin (%) 9.673.926.5444.2514.98
PBT Margin (%) 8.03-0.83-14.1530.52-16.39
Net Profit Margin (%) 5.72-2.35-14.1319.80-11.69
NP After MI And SOA Margin (%) 5.78-2.23-14.1920.09-13.39
Return on Networth / Equity (%) 7.73-3.65-29.07292.380.00
Return on Capital Employeed (%) 10.333.665.1299.579.17
Return On Assets (%) 4.54-1.58-8.7121.01-6.08
Long Term Debt / Equity (X) 0.170.611.384.63-5.84
Total Debt / Equity (X) 0.350.811.559.66-6.24
Asset Turnover Ratio (%) 0.830.720.550.820.30
Current Ratio (X) 1.451.351.360.520.59
Quick Ratio (X) 1.181.091.140.440.50
Inventory Turnover Ratio (X) 12.5713.463.054.312.23
Interest Coverage Ratio (X) 8.873.511.715.130.81
Interest Coverage Ratio (Post Tax) (X) 4.490.540.513.230.65
Enterprise Value (Cr.) 396.90401.32381.55501.74229.87
EV / Net Operating Revenue (X) 2.873.614.102.592.67
EV / EBITDA (X) 19.6823.3718.854.8610.82
MarketCap / Net Operating Revenue (X) 2.603.153.452.000.86
Price / BV (X) 3.485.147.0729.17-2.89
Price / Net Operating Revenue (X) 2.603.153.452.000.86
EarningsYield 0.02-0.01-0.040.10-0.15

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 134.70 Cr. and Equity Capital is Rs. 35.69 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals4801/B & 4802/A, Ankleshwar Gujarat 393002Contact not found
Management
NamePosition Held
Mr. Babulal JainChairman
Mr. Kunal GandhiManaging Director & CEO
Mr. Yogesh B ShahWholeTime Director & CFO
Mr. Shashil MendosaNon Executive Director
Mr. Prashant GodhaNon Executive Director
Mrs. Dhara ShahIndependent Director
Mr. Neeraj GolasIndependent Director
Ms. Archana S YadavIndependent Director

FAQ

What is the intrinsic value of Lyka Labs Ltd and is it undervalued?

As of 20 April 2026, Lyka Labs Ltd's intrinsic value is ₹29.05, which is 43.26% lower than the current market price of ₹51.20, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (9.31 %), book value (₹28.3), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Lyka Labs Ltd?

Lyka Labs Ltd is trading at ₹51.20 as of 20 April 2026, with a FY2026-2027 high of ₹129 and low of ₹44.1. The stock is currently near its 52-week low. Market cap stands at ₹183 Cr..

How does Lyka Labs Ltd's P/E ratio compare to its industry?

Lyka Labs Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Lyka Labs Ltd financially healthy?

Key indicators for Lyka Labs Ltd: ROCE of 9.91 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.00 %.

Is Lyka Labs Ltd profitable and how is the profit trend?

Lyka Labs Ltd reported a net profit of ₹8 Cr in Mar 2025 on revenue of ₹138 Cr. Compared to ₹38 Cr in Mar 2022, the net profit shows a declining trend.

Does Lyka Labs Ltd pay dividends?

Lyka Labs Ltd has a dividend yield of 0.00 % at the current price of ₹51.20. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lyka Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports